EU Reaches Deal on New Medical Device Regulations

| Printer friendly version

The European Parliament and European Council recently jointly announced an agreement regarding new rules on medical devices and in vitro diagnostic medical devices.  The process that lead to the agreement began in 2012.  According to the press release, the goal of these new regulations is to:

mak[e] sure that medical devices and in vitro diagnostic medical devices are safe while allowing patients to benefit [from] innovative health care solutions in a timely manner.

The press release notes that the draft regulations will accomplish these goals by strengthening the rules on placing devices on the market and tightening surveillance once they are available.  Regarding the agreement, Edith Schippers, Minister of Health of the Netherlands and President of the EU Council stated:

The deal reached will improve patients’ health and it will help to enhance the quality of life of disabled persons. It will also ensure a level playing field for the 25 000 medical devices manufacturers in the EU, many of which are SMEs and which employ more than half a million persons.

Organizations such as the European Society for Cardiology and MedTech Europe have hailed the agreement as a significant step forward.  Serge Bernasconi, CEO of MedTech Europe said:

The medical industry recognises the importance of these updated regulations. The implementation will require substantial resources from all stakeholders, including industry. It is thus essential to keep the overarching goals of patient safety and innovation in mind during the translation into implementable rules.

If the Parliament’s ENVI Committee (i.e., the Committee on Environment, Public Health and Food Safety) and the EU Council confirm the agreement later this year, the new rules will apply three years after publication for medical devices and five years after publication for in vitro diagnostic medical devices.  A draft of the new regulations is not yet available, but the press release provides the following notable details on the expected content.

Expected Impact of Draft Regulations on Device Manufacturing

  • “[F]urther tighten the rules for the independent bodies that are responsible for assessing medical devices before they can be placed on the market”
  • “[S]trengthen the surveillance of these so-called notified bodies by national authorities”
  • Give the notified bodies “the right and duty to carry out unannounced factory inspections”
  • Manufacturers will be responsible for “the follow-up of the quality, performance and safety of devices placed on the market”
  • “Manufacturers and other economic operators will have clear responsibilities, for instance on liability, but also on registering complaints on devices”
  • Improved availability “of clinical data on devices”
  • Strengthen the protection for “patients participating in clinical investigations”
  • Increased checks by experts for certain high risk devices

Expected Impact of Draft Regulations on Transparency and Traceability 

  • Creation of a central database for “all relevant information”
    • “It will cover economic operators, notified bodies, market surveillance, vigilance, clinical investigations and certificates”
    • “It will provide patients, healthcare professionals and the public with comprehensive information on products available in the EU”
  • “Patients who are implanted with a device will be given key information on the product, including any precautions which might need to be taken”
Brandon Smith
Brandon Smith is an associate in our Orange County office. His practice is focused on patent litigation and prosecution. Mr. Smith earned his Bachelor's of Science in Biomedical Engineering at California Polytechnic University, San Luis Obispo. Mr. Smith received his J.D. from the University of San Diego School of Law where he was Editor-in-Chief of Volume 52 of the San Diego Law Review. Mr. Smith was a summer associate with the firm in 2014 and joined the firm as an associate in 2015.
Click here to read full bio
View all posts published by Brandon Smith »

Leave a Reply

By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.